Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a multicentre study examining the effectiveness of angiotension converting enzyme
inhibitor (ACEI), angiotensin receptor blocker (ARB) or a combination of both in reducing the
rate of decline in residual renal function (RRF) in continuous ambulatory peritoneal dialysis
(CAPD) patients.